Member Info for BurtonD

The #HVO team are delighted to be attending the 9th @ESWInfluenza Conference in Valencia on 17-20 September

https://eswiconference.org/symposium/SPS01/

Does this help. This is the way i see it...

It's a purely a procedural process allowing the Company to reduce the nominal value of its shares from 1p to 0.1p WITHOUT diluting existing shareholders as the Companies Act prohibits companies from issuing shares at below the nominal value.

It'll have ZERO impact on shareholders - no new ordinary shares are being issued.

The reason for it is to allow the company to take advantage of the general authority to issue new shares (up to 20% of share capital only) it's requesting at the AGM - that means the Company is able to be more agile as and when it wants to raise some cash.

This is all subject to a shareholder vote at the AGM so is entirely in shareholder control.

There's no impact on existing warrants currently issued by the company, which have a 5p/share exercise price.

There's nothing fishy going on!

Amy more thoughts or questions please send to me and i can try and pass on to the BOD if thats helps?

david burton.tms@gmail.com

“…Elsewhere, @hVIVO_UK settled at a six-month high of 19½p, after rising 1¼p, or 6.9 per cent, as the Aim-listed drugs trial operator hailed “another period of excellent growth”

https://www.thetimes.co.uk/article/6e0736b0-518f-11ee-abb5-ce4135341f1b?shareToken=df86eb0535d704f9d7857298a95f2f39

In case you missed last nights' @investormeetco presentation by the HVO CEO & CFO on the Interim Results H1 2023, you can now watch the full recording here:

https://www.youtube.com/watch?v=ut3Tv9-m7w4

Terrific write up in the @IChronicle for @hVIVO_UK

“…Another upgrade makes this takeover target a buy. #HVO has upgraded guidance and there is increasing bid activity in the sector…”

✅First-half cash profit rises 126 per cent to £5.2mn

✅52 per cent higher revenue of £27.3mn

✅Cash profit margin expands from 12.6 to 19.1 per cent

✅Net cash has doubled to £31.3mn (4.6p) in past 12 months

✅Analysts upgrade 2023 and 2024 EPS estimates by 62 per cent and 46 per cent

https://www.investorschronicle.co.uk/ideas/2023/09/12/bumper-upgrades-make-this-takeover-target-a-buy/

DM me on Twitter / X for full note if required. @Davidburton1971

“…With a low operational burn and strong financial discipline, we ended the period with a robust financial position of £14.1m cash…”

Cathal Friel

Chairman and Co-Founder

https://polaris.brighterir.com/public/poolbeg_pharma/news/rns/story/x2el0lx

“…We’re in a really, really excellent financial position and we’re a small board, and we can manoeuvre quite quickly. We’re quite dynamic in the way we operate…”

Video below:

https://youtu.be/TjgqAhUxz14

✅ Significant financial & operational growth in H1 23

✅Increasing no. & size of challenge trials

✅Facilities expansion; increasing revenue potential & enhancing long term margins

✅Positive outlook

https://m.youtube.com/watch?v=PXrCvG-Tkyk

Interim Results #HVO

↗️Revenue up 52% = £27.3m

📈EBITDA >doubled = £5.2m

💵Net cash = £31.3m at 30 June

💪FY23 Revenue upgrade = £55m

⬆️ FY23 EBITDA margin upgrade = c.19%

📣Nominal Annual Dividend = details to be announced with FY23 audited results

https://polaris.brighterir.com/public/hvivo/news/rns/story/rgz9g3w

The HVO VP of Regulatory Affairs featured in @pharmafocusasia on how Human Challenge Trials can establish early efficacy for #vaccines & #therapeutics for infectious disease & can be a tool to enhance the success rate for clinical development

(pg 56-59)

https://www.pharmafocusasia.com/latest-ebook

NO PLACING. Ignore the luantics. Just spoken to JA

NO PLACING. Ignore the idiots. Just spoken to JA. All good...

Ignore this rubbish. NO PLACING. Just spoken to JA

NO PLACING. Ignore the haters. Just spoken to JA. All good

NO PLACING. Just spoken to JA. Ignore the haters

A few "silly" rumours on here which we are working with LSE on removing and blocking posters. Spoken to JA, and he is most annoyed. Clear message is NO PLACING.

I think maybe you are getting a little confused by Gemfields numbers.

These include beryl in their production figures, and URAH are only referring to gemstone quality material, hence the 3m carats number Vs the 29m carats by Gemfileds.

Hope that helps?

@EncOVac_ is developing a platform for the #encapsulation of vaccines for a wide range of infectious diseases, representing a significant commercial opportunity.

Learn more about the programmes & the strong expertise behind the technology here:

https://www.poolbegpharma.com/pipeline/oral-vaccine-platform/

“…a huge significant additional resource that is classified as JORC exploration target, that is between 166 to 344 million carats, is still in this deposit…”

https://total-market-solutions.com/2023/09/ura-holdings-plc-september-2023/